Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
55 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cross Cancer Institute
Edmonton, Alberta, Canada
- London Health Science Center
London, Ontario, Canada
- Chum Hopital Notre Dame
Montreal, Quebec, Canada
- Jewish General Hospital
Montreal, Quebec, Canada
- Centre Hospitalier Départemental Les Oudairies
La Roche-sur-Yon, France
- Centre Léon Bérard
Lyon, France
- Clinique Hartmann
Neuilly-sur-Seine, France
- Institut Curie
Paris, France
- Charite Campus Benjamin Franklin
Berlin, Germany
- University Hospital Charite
Berlin, Germany
- Universitat Bonn
Bonn, Germany
- Universitatsklinikum Erlangen
Erlangen, Germany
- Universitatsklinikum Hamburg Eppendorf
Hamburg, Germany
- Universitatsklinikum Des Saarlandes
Homburg, Germany
- Klinikum Kassel
Kassel, Germany
- Rotkreuzkrankenhaus Munchen
Munich, Germany
- Universitats Frauenklinik Tubingen
Tübingen, Germany
- St Jame'S Hospital
Dublin, Ireland
- Waterford Regional Hospital
Waterford, Ireland
- Meir Medical Center
Kfar Saba, Israel
- Sheba Medical Center
Ramat Gan, Israel
- Kaplan Medical Center
Rehovot, Israel
- Sourasky Medical Center
Tel Aviv, Israel
- Asaf Harofe Mc
Zrifin, Israel
- Hospital Clinic I Provincial
Barcelona, Spain
- Hospital Universitario de Guadalajara
Guadalajara, Spain
- Hospital U 12 de Octubre
Madrid, Spain
- Hospital Universitario de Tenerife
San Cristóbal de La Laguna, Spain
- Hospital Universitario Virgen Macarena de Sevilla
Seville, Spain
- Saint James'S University Hospital
Leeds, United Kingdom
- University College London
London, United Kingdom
- Mount Vernon Cancer Centre
Northwood, United Kingdom
- Central Hematology Oncology Medical Group Inc.
Alhambra, California, United States
- Providence Saint Joseph Medical Center
Burbank, California, United States
- St Jude Heritage Healthcare
Fullerton, California, United States
- Wilshire Oncology Medical Group Inc
La Verne, California, United States
- Cedars-Sinai Medical Center
Los Angeles, California, United States
- Ucla
Los Angeles, California, United States
- University of Southern California
Los Angeles, California, United States
- North Valley Hematology/oncology Medical Group
Northridge, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2009
- Primary completion
- 30 Sept 2013
- Completion
- 30 Nov 2014
- Last update posted
- 12 Jan 2016
- Registered enrollment
- 170
- Registry id
- NCT00718523
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.